NPHS2 stomatin family member, podocinGenealiases: PDCN · SRN1
Q-omics provides the consensus-scored NPHS2 profile across patient tissues and cancer cell-line models. NPHS2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NPHS2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, NPHS2 protein abundance shows 7,857 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight LIHC, KIRC, and CCRCC as cancer lineages where NPHS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPHS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPHS2 survival associations across molecular data types. NPHS2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPHS2 RNA expression–survival associations across cancer types. High NPHS2 expression shows unfavorable associations in LIHC, THCA, LUAD, ESCA, CESC and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NPHS2 RNA expression.
This table summarizes NPHS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NPHS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPHS2 shows lower tumor expression in KIRC, KIRP, KICH and COAD and higher tumor expression in BRCA and CHOL. The KIRC box plot shows higher NPHS2 RNA expression in normal versus tumor tissue (log2 FC = −6.760, t-test p < 0.001).
This table shows molecular features associated with NPHS2 in patient tissues and cancer cell lines. In patient samples, NPHS2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NPHS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
